Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Villoslada

Showing results (31-40 of 207) with videos related to

Pageof 21
Sort By:
Neurology|May 12, 2004
Clinical characteristics of responders to interferon therapy for relapsing MSPablo Villoslada, Jorge R Oksenberg, Jordi Rio, et al.
Scientific Reports|March 29, 2023
A Phase 1 randomized study on the safety and pharmacokinetics of OCS-05, a neuroprotective disease modifying treatment for Acute Optic Neuritis and Multiple SclerosisPablo Villoslada, Mar Masso, Stephane Paris, et al.
Annals of the New York Academy of Sciences|February 9, 2005
No evidence of pancreatic autoimmunity among patients with multiple sclerosisJ Ramón Bilbao, Pablo Villoslada, Ainhoa Martin-Pagola, et al.
Journal of Neuroimmunology|August 16, 2005
Chromosome 5 and multiple sclerosisRicardo Palacios, Ion Aguirrezabal, Begona Fernandez-Diez, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 23, 2025
The Present and Future of Monoclonal Antibody Therapies for Multiple SclerosisSilvia Susin-Calle, Elvira Munteis, Pablo Villoslada, et al.
The Lancet. Neurology|August 2, 2016
Phenytoin for neuroprotectionElena H Martinez-Lapiscina, Magi Andorra, Bernardo Sanchez-Dalmau, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 1, 2012
Color vision is strongly associated with retinal thinning in multiple sclerosisPablo Villoslada, Ami Cuneo, Jeffrey Gelfand, et al.
Plos Computational Biology|October 17, 2025
Multiscale networks in Alzheimer's disease identify brain hypometabolism as central across biological scalesElena Lara-Simon, Juan Domingo Gispert, Jordi Garcia-Ojalvo, et al.
Expert Opinion on Investigational Drugs|February 25, 2025
Ongoing phase 2 agents for multiple sclerosis: could we break the phase 3 trial deadlock?Silvia Susin-Calle, Jose Enrique Martinez-Rodriguez, Elvira Munteis, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 9, 2004
Genetic analysis of SLC11A1 polymorphisms in multiple sclerosis patientsManuel Comabella, Laura Altet, Francesc Peris, et al.
Pageof 21

Showing results (31-40 of 207) with videos related to

Sort By:
Pageof 21
Neurology|May 12, 2004
Clinical characteristics of responders to interferon therapy for relapsing MSPablo Villoslada, Jorge R Oksenberg, Jordi Rio, et al.
Scientific Reports|March 29, 2023
A Phase 1 randomized study on the safety and pharmacokinetics of OCS-05, a neuroprotective disease modifying treatment for Acute Optic Neuritis and Multiple SclerosisPablo Villoslada, Mar Masso, Stephane Paris, et al.
Annals of the New York Academy of Sciences|February 9, 2005
No evidence of pancreatic autoimmunity among patients with multiple sclerosisJ Ramón Bilbao, Pablo Villoslada, Ainhoa Martin-Pagola, et al.
Journal of Neuroimmunology|August 16, 2005
Chromosome 5 and multiple sclerosisRicardo Palacios, Ion Aguirrezabal, Begona Fernandez-Diez, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 23, 2025
The Present and Future of Monoclonal Antibody Therapies for Multiple SclerosisSilvia Susin-Calle, Elvira Munteis, Pablo Villoslada, et al.
The Lancet. Neurology|August 2, 2016
Phenytoin for neuroprotectionElena H Martinez-Lapiscina, Magi Andorra, Bernardo Sanchez-Dalmau, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 1, 2012
Color vision is strongly associated with retinal thinning in multiple sclerosisPablo Villoslada, Ami Cuneo, Jeffrey Gelfand, et al.
Plos Computational Biology|October 17, 2025
Multiscale networks in Alzheimer's disease identify brain hypometabolism as central across biological scalesElena Lara-Simon, Juan Domingo Gispert, Jordi Garcia-Ojalvo, et al.
Expert Opinion on Investigational Drugs|February 25, 2025
Ongoing phase 2 agents for multiple sclerosis: could we break the phase 3 trial deadlock?Silvia Susin-Calle, Jose Enrique Martinez-Rodriguez, Elvira Munteis, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 9, 2004
Genetic analysis of SLC11A1 polymorphisms in multiple sclerosis patientsManuel Comabella, Laura Altet, Francesc Peris, et al.
Pageof 21